Evaluating the Addition of Bevacizumab to Endocrine Therapy as first-line treatment for Hormone-receptor positive metastatic breast cancer: A Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

BACKGROUND: Randomized trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET+bevacizumab (Bev) in 1st line hormone-receptor positive metastatic breast cancer (MBC) patients have thus far shown conflicting results. PATIENTS AND METHODS: We pooled data from two simila...

詳細記述

保存先:
書誌詳細
出版年:Eur J Cancer
主要な著者: Martín, M., Loibl, S., Hyslop, T., De la Haba-Rodríguez, J., Aktas, B., Cirrincione, C. T., Mehta, K., Barry, W. T., Morales, S., Carey, L. A., Garcia-Saenz, J. A., Partridge, A., Martinez-Jañez, N., Hahn, O., Winer, E., Guerrero-Zotano, A., Hudis, C., Casas, M., Rodriguez-Martin, C., Furlanetto, J., Carrasco, E., Dickler, M. N.
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718694/
https://ncbi.nlm.nih.gov/pubmed/31276981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.06.002
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料